IGF2BP3 and acute myeloid leukemia: In acute myeloid leukemia (AML), AML-derived mesenchymal stem cells (AML-MSCs) deliver METTL14 to leukemia cells via exosomes, where it stabilizes ROCK1 expression through the m6A-IGF2BP3 axis, thereby mediating radioresistance.